WALTHAM, Mass., Jan 12 (Bernama-GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced that the first patient has been dosed in the INDIGO Phase 3 registrational study of obexelimab. The INDIGO study will evaluate the clinical efficacy and safety of obexelimab treatment in the prevention of IgG4-related disease (IgG4-RD) flare. Obexelimab is a high-affinity bifunctional antibody that inhibits B-cell lineages by simultaneously binding to CD19 and FcүRIIB, thereby downregulating B-cell activity in patients with autoimmune diseases associated with autoantibodies, such as IgG4-RD.
- January 12, 2023
0
291
Less than a minute
You can share this post!
administrator
Related Articles
LYB lays foundation for 1st industrial-scale advanced recycling…
- September 20, 2024
EBC Bags BrokersView Best Trading Experience Award, Strengthening…
- September 20, 2024
Menlo Security Named a Leader in GigaOm Radar…
- September 20, 2024